{"name":"Xiaohua Wu MD","slug":"xiaohua-wu-md","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Etoposide, Cyclophosphamide, Carboplatin","genericName":"Etoposide, Cyclophosphamide, Carboplatin","slug":"etoposide-cyclophosphamide-carboplatin","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"Etoposide, Cyclophosphamide, Carboplatin","genericName":"Etoposide, Cyclophosphamide, Carboplatin","slug":"etoposide-cyclophosphamide-carboplatin","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxOdjFHdEpSSU1manRob3BTbFpDQ2M2dlZGSXNWYkpLYlF3R3FGUXdzb1BEOEhuVlVwY0tDUVpWeDBqRDBQRGpJQmEwakxXQkx1MUlqRlBWMFVtOGFGRnFOTG9CaXhtb3VLb0t2bC1zbGQ4LUpqWFJSQ1pDcmJLX1Y3WHUtckFJakRSUzM5a0hpREp5Nk1DRHo4UW54QVEyeXFKUGFGUTBoZGlDR1RHSGk3NG9PSXZmQ0xsN2dmbm9wRWJkX1VQTS1qUA?oc=5","date":"2025-07-21","type":"pipeline","source":"ascopost.com","summary":"Camrelizumab Plus Famitinib vs Camrelizumab Alone in Recurrent or Metastatic Cervical Cancer - ascopost.com","headline":"Camrelizumab Plus Famitinib vs Camrelizumab Alone in Recurrent or Metastatic Cervical Cancer","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}